HRS-1893

Unknown / undisclosed

Phase 3underway

Evidence outlook · registrational

Hypertrophic Cardiomyopathy: registrational readout pending

Its supporting mid-stage studies have completed. The registry's posted readout date (2026-09) has passed without a status update. Check News for topline announcements.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Hypertrophic Cardiomyopathy
NCT07021976 · Shandong Suncadia Medicine Co., Ltd.
2025-08-11 – 2026-11 · Obstructive Hypertrophic Cardiomyopathy
What this study did
Phase 2 (4)
Hypertrophic Cardiomyopathy
NCT07021963 · Shandong Suncadia Medicine Co., Ltd.
2025-07-04 – 2027-12 · Hypertrophic Cardiomyopathy
What this study did
NCT06816251 · Shandong Suncadia Medicine Co., Ltd.
2025-02-25 – 2025-11-18 · Non-obstructive Hypertrophic Cardiomyopathy
What this study did
NCT06516068 · Shandong Suncadia Medicine Co., Ltd.
2024-08-11 – 2025-08 · Obstructive Hypertrophic Cardiomyopathy
What this study did
Other / comorbidity
NCT07269717 · Shandong Suncadia Medicine Co., Ltd.
2026-03-30 – 2027-05 · Heart Failure With Preserved Ejection Fraction
What this study did
Phase 1 (7)
Hypertrophic Cardiomyopathy
NCT07033455 · Atridia Pty Ltd.
2025-06-25 – 2025-10-30 · Hypertrophic Cardiomyopathy
What this study did
NCT06775834 · Shandong Suncadia Medicine Co., Ltd.
2025-02-11 – 2025-07-23 · Hypertrophic Cardiomyopathy
What this study did
NCT06354556 · Shandong Suncadia Medicine Co., Ltd.
2024-04-26 – 2024-05-20 · Obstructive Hypertrophic Cardiomyopathy
What this study did
NCT05879523 · Shandong Suncadia Medicine Co., Ltd.
2023-06-05 – 2024-03-21 · Obstructive Hypertrophic Cardiomyopathy
What this study did
Other / comorbidity
NCT07479641 · Shandong Suncadia Medicine Co., Ltd.
2026-04-14 – 2026-09-14 · Cardiomyopathy
What this study did
NCT07656779 · Shandong Suncadia Medicine Co., Ltd.
2026-06 – 2026-07 · Cardiomyopathies
What this study did
NCT07272330 · Shandong Suncadia Medicine Co., Ltd.
2025-12-11 – 2026-03-21 · Cardiomyopathy
What this study did

Competitive landscape

4 other tracked programmes target this mechanism, 2 of them ahead of this one.

This drug's own stage for Hypertrophic Cardiomyopathy: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
HRS-1893: this drugPhase 3UndisclosedCardiac myosin (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
Aficamten (Myqorzo)ApprovedSmall moleculeCardiac myosin (inhibitor)Reliable signal
NCT05767346: Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET) (Baseline to Week 24): Aficamten 1.07 mL/kg/min (Standard Deviation 2.767) | Metoprolol -1.24 mL/kg/min (Standard Deviation 2.186)
NCT05186818: Change From Baseline in pVO2 at Week 24 (Baseline to Week 24): Aficamten up to 20 mg 1.76 mL/kg/min (Standard Error 0.25) | Placebo to Match Aficamten 0.02 mL/kg/min (Standard Error 0.25)
Mavacamten (Camzyos)ApprovedSmall moleculeCardiac myosin (inhibitor)Partial signal
NCT04349072: Composite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 16 (Week 16): Mavacamten 10 Participants | Placebo to Mavacamten 43 Participants
Propranolol (Inderal LA)ApprovedSmall moleculeBeta-1/beta-2 adrenergic receptorsnot yet gradedNo reviewed efficacy summary in this indication
Sotagliflozin (Inpefa)Phase 3Small moleculeSGLT1/2 (dual)not yet gradedNo reviewed efficacy summary in this indication
Delocamten
Phase 2(overall)
Small moleculeCardiac myosin (inhibitor)
not yet graded(overall)
No reviewed efficacy summary in this indication
Ninerafaxstat (IMB-101)Phase 2Small moleculeCardiac fatty-acid oxidationnot yet gradedNo reviewed efficacy summary in this indication
Ulacamten
Phase 2(overall)
Small moleculeCardiac myosin (inhibitor)
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow HRS-1893 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
March 2027 (1)
Phase 2Heart Failure With Preserved Ejection FractionRecruiting
Est. primary completion 2027-03 · NCT07269717 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Hypertrophic CardiomyopathyRecruiting
Est. primary completion 2027-12 · NCT07021963 · CT.gov ↗
What to watch

See the full readout calendar ↗